We recently discovered that coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS mutant lung adenocarcinoma. Nevertheless

 

Abstract

We recently discovered that coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS mutant lung adenocarcinoma. Nevertheless, the evident toxicity restricts the use of wild-type (WT)-CVB3 for cancer therapy. The current study aims to engineer the CVB3 to decrease its toxicity and to extend our previous research to determine its safety and efficacy in treating TP53/RB1 mutant small-cell lung cancer (SCLC). A microRNA-modified CVB3 (miR-CVB3) was generated via inserting multiple copies of tumor-suppressive miR-145/miR-143 target sequences into the viral genome. In vitro experiments revealed that miR-CVB3 retained the ability to infect and lyse KRAS mutant lung adenocarcinoma and TP53/RB1-mutant SCLC cells, but with a markedly reduced cytotoxicity toward cardiomyocytes. In vivo study using a TP53/RB1-mutant SCLC xenograft model demonstrated that a single dose of miR-CVB3 via systemic administration resulted in a significant tumor regression. Most strikingly, mice treated with miR-CVB3 exhibited greatly attenuated cardiotoxicities and decreased viral titers compared to WT-CVB3-treated mice. Collectively, we generated a recombinant CVB3 that is powerful in destroying both KRAS mutant lung adenocarcinoma and TP53/RB1-mutant SCLC, with a negligible toxicity toward normal tissues. Future investigation is needed to address the issue of genome instability of miR-CVB3, which was observed in ~40% of mice after a prolonged treatment.

PMID: 32123721 [PubMed]

13:31

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:31

In reply to this message

pubmed: ctoall&ca or conall

[Immune checkpoint inhibitor-related cardiotoxicities].

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--medjournals.cn-CMAPH-Linkout-logo.png //www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--journal.yiigle.com-r-cms-jiansuo-CMAPH-Linkout-logo.png Related Articles

[Immune checkpoint inhibitor-related cardiotoxicities].

Zhonghua Nei Ke Za Zhi. 2020 01 01;59(1):75-77

Authors: Zhou L, Li HW, Chen H

PMID: 31887842 [PubMed - indexed for MEDLINE]

13:31

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:31

In reply to this message

pubmed: ctoall&ca or conall

Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--pubs.acs.org-images-pubmed-acspubs.jpg Related Articles

Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

J Med Chem. 2019 03 28;62(6):3135-3146

Authors: Huang W, Hulverson MA, Choi R, Arnold SLM, Zhang Z, McCloskey MC, Whitman GR, Hackman RC, Rivas KL, Barrett LK, Ojo KK, Van Voorhis WC, Fan E